Age-related Macular Degeneration Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight's, "Age-Related Macular Degeneration Pipeline Insight 2026" report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Age-Related Macular Degeneration pipeline landscape. It covers the Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Age-Related Macular Degeneration Pipeline? @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Age-Related Macular Degeneration Pipeline Report

* On May 28, 2026- Biobizkaia Health Research Institute initiated a study is intended to be performed in the ophthalmology departments or ophthalmology clinics of the participating sites, located in Spain. Macular degeneration is an eye disease characterised by progressive damage to the macula leading to a loss of central vision. There are two types of macular degeneration, dry and wet or exudative. The prevalence of the latter in Spain is 1.9% in people aged 65 and over. Among the subtypes of macular neovascularisation (MNV), type 2 is rare (9%), with the majority being mixed type 1 and 2 cases (13.5%). SHRM is present in about 77% of eyes with neovascular age-related macular degeneration (AMD).
* On May 27, 2026- AbbVie announced a Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
* On May 20, 2026- Stealth BioTherapeutics Inc. conducted a clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.
* On May 14, 2026- Boehringer Ingelheim initiated a study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy.
* DelveInsight's Age-Related Macular Degeneration Pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for Age-Related Macular Degeneration treatment.
* The leading Age-Related Macular Degeneration Companies such as Stealth BioTherapeutics, Sanofi, Merck, HuidaGene Therapeutics, ONL Therapeutics, Molecular Therapeutics, Evergreen Therapeutics, Caregen Co. Ltd., SCAI Therapeutics, Frontera Therapeutics, Chengdu Origen Biotechnology Co., Ltd., BenoBio, Skyline Therapeutics, Perceive Biotherapeutics, Sinocelltech Ltd., Tangram Therapeutics, Character Biosciences, Amarna Therapeutics, Avirmax Biopharma, Galimedix Therapeutics, Rallybio, Ikarovec, 4P Pharma, Surrozen, Beacon Therapeutics, Ray Therapeutics and others.
* Promising Age-Related Macular Degeneration Therapies such as rhuFab V2 (ranibizumab), VOY-101, Anecortave Acetate, bevacizumab, ranibizumab, KH658, Iptacopan (LNP023), MG-O-1002, Brolucizumab and others.

Want to know which companies are leading innovation in Age-Related Macular Degeneration? @ Age-Related Macular Degeneration Clinical Trials Assessment [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Age-Related Macular Degeneration Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Age-Related Macular Degeneration Pipeline Report also highlights the unmet needs with respect to the Age-Related Macular Degeneration.

Age-Related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a progressive disorder of the macula and a leading cause of central vision loss in the elderly population. It primarily affects the outer retina, including photoreceptors and the retinal pigment epithelium (RPE), with early accumulation of drusen indicating impaired cellular waste clearance. As the disease advances, chronic inflammation, reduced choroidal blood flow, and RPE dysfunction contribute to photoreceptor degeneration and vision decline. Clinically, AMD progresses from early to late stages, manifesting as the slower dry form (geographic atrophy) or the more aggressive wet (neovascular) form driven by abnormal blood vessel growth. Patients typically experience central visual disturbances such as blurriness, distortion, or scotomas, while peripheral vision remains preserved, with symptoms often worsening rapidly in wet AMD due to fluid leakage or hemorrhage.

Age-Related Macular Degeneration Emerging Drugs Profile

* Elamipretide: Stealth BioTherapeutics

Elamipretide is a mitochondria-targeted peptide developed to enhance cellular energy generation and limit oxidative stress, both of which play a significant role in age-related macular degeneration. It acts by stabilizing cardiolipin within the inner mitochondrial membrane, thereby supporting the function of photoreceptors and retinal pigment epithelium cells. In AMD, especially the dry form, this approach is intended to slow retinal deterioration and help maintain visual function over time. The therapy is currently under evaluation in a Phase III clinical trial for patients with age-related macular degeneration.

* 4D-150: 4D Molecular Therapeutics

4D-150 is an investigational intravitreal gene therapy being developed for neovascular (wet) age-related macular degeneration (AMD). It uses a customized AAV vector to deliver genes encoding anti-VEGF biologics, enabling sustained intraocular production of therapeutic proteins. By providing long-term suppression of VEGF, it aims to reduce treatment burden and control retinal fluid and neovascularization. The therapy is currently in Phase III stage of its clinical development.

* MK-8748: Merck

MK-8748 (Tiespectus) is an investigational bispecific antibody being developed for neovascular (wet) age-related macular degeneration (AMD). It simultaneously activates the Tie2 pathway and inhibits vascular endothelial growth factor (VEGF), targeting vascular instability and leakage in the retina. This dual mechanism aims to stabilize retinal blood vessels, reduce fluid accumulation, and preserve visual function. The therapy is currently being evaluated in a pivotal Phase IIb/III clinical trial (MALBEC) for patients with wet AMD.

* SAR402663: Sanofi

SAR402663 is an investigational one-time intravitreal gene therapy being developed for neovascular (wet) age-related macular degeneration (AMD). It delivers genetic material encoding soluble FLT01, which inhibits vascular endothelial growth factor (VEGF) to suppress abnormal blood vessel growth. By reducing vascular leakage and retinal damage, it aims to preserve vision and address the underlying disease pathology. The therapy is currently in Phase II clinical evaluation and has received fast track designation from the FDA.

* Xelafaslatide: ONL Therapeutics

Xelafaslatide is an investigational first-in-class small molecule Fas inhibitor being developed for geographic atrophy associated with dry age-related macular degeneration (AMD). It works by blocking Fas-mediated cell death pathways, thereby protecting retinal cells such as photoreceptors from degeneration. By preserving retinal structure, it aims to slow disease progression and maintain visual function. The therapy is currently being evaluated in a global Phase II clinical trial for patients with dry AMD-related geographic atrophy.

* HG202: HuidaGene Therapeutics

HG202 is an investigational CRISPR/Cas13-based RNA-editing therapy being developed for neovascular (wet) age-related macular degeneration (AMD). It utilizes a single AAV vector to deliver RNA-editing machinery that selectively knocks down VEGF-A mRNA, a key driver of abnormal blood vessel growth. By reducing VEGF expression, it aims to inhibit choroidal neovascularization and provide a durable, potentially one-time treatment option. The therapy is currently in early Phase I clinical evaluation following FDA IND clearance.

If you're tracking ongoing Age-Related Macular Degeneration Clinical trials, this press release is a must-read @ Age-Related Macular Degeneration Treatment Drugs [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-Related Macular Degeneration Companies

Stealth BioTherapeutics, Sanofi, Merck, HuidaGene Therapeutics, ONL Therapeutics, Molecular Therapeutics, Evergreen Therapeutics, Caregen Co. Ltd., SCAI Therapeutics, Frontera Therapeutics, Chengdu Origen Biotechnology Co., Ltd., BenoBio, Skyline Therapeutics, Perceive Biotherapeutics, Sinocelltech Ltd., Tangram Therapeutics, Character Biosciences, Amarna Therapeutics, Avirmax Biopharma, Galimedix Therapeutics, Rallybio, Ikarovec, 4P Pharma, Surrozen, Beacon Therapeutics, Ray Therapeutics and others.

The Age-Related Macular Degeneration Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Age-Related Macular Degeneration with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Age-Related Macular Degeneration Treatment.
* Age-Related Macular Degeneration Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Age-Related Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Age-Related Macular Degeneration market.

Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Age-Related Macular Degeneration Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

The Age-Related Macular Degeneration Pipeline Report covers it all @ Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Age-Related Macular Degeneration Pipeline Report

* Coverage- Global
* Age-Related Macular Degeneration Companies- Stealth BioTherapeutics, Sanofi, Merck, HuidaGene Therapeutics, ONL Therapeutics, Molecular Therapeutics, Evergreen Therapeutics, Caregen Co. Ltd., SCAI Therapeutics, Frontera Therapeutics, Chengdu Origen Biotechnology Co., Ltd., BenoBio, Skyline Therapeutics, Perceive Biotherapeutics, Sinocelltech Ltd., Tangram Therapeutics, Character Biosciences, Amarna Therapeutics, Avirmax Biopharma, Galimedix Therapeutics, Rallybio, Ikarovec, 4P Pharma, Surrozen, Beacon Therapeutics, Ray Therapeutics and others.
* Age-Related Macular Degeneration Therapies- rhuFab V2 (ranibizumab), VOY-101, Anecortave Acetate, bevacizumab, ranibizumab, KH658, Iptacopan (LNP023), MG-O-1002, Brolucizumab and others.
* Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Age-Related Macular Degeneration Treatment landscape in this detailed analysis @ Age-Related Macular Degeneration Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Age-related macular degeneration (AMD): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Age-related macular degeneration (AMD)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug profiles in the detailed report.....
* Inactive Products
* Age-related macular degeneration (AMD) Key Companies
* Age-related macular degeneration (AMD) Key Products
* Age-related macular degeneration (AMD)- Unmet Needs
* Age-related macular degeneration (AMD)- Market Drivers and Barriers
* Age-related macular degeneration (AMD)- Future Perspectives and Conclusion
* Age-related macular degeneration (AMD) Analyst Views
* Age-related macular degeneration (AMD) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=agerelated-macular-degeneration-pipeline-appears-robust-with-90-key-pharma-companies-actively-working-in-the-domain-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.